Science AI Journal
Medicine · Research topic

Open research questions in Monoclonal and Polyclonal Antibodies Research

380 gap statements mined from Monoclonal and Polyclonal Antibodies Research papers in our 7.9M-paper local library, which holds 2,389 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Monoclonal and Polyclonal Antibodies Research? See the ranked Medicine journals.

What the literature leaves open

  • Prior methods focus on single-site mutations or combinations of individually favorable mutations, limiting their ability to capture higher-order dependencies among multiple positions. Most methods still focus primarily on a single property, leaving the joint optimization of multiple antibody properties insufficiently addressed.

    Multiproperty optimization of therapeutic antibodies through sequence editing via large language model and reinforcement learning · 2026 · DOI

  • The lack of knowledge about how RNA binding proteins are anchored to the membrane of tumor cells. The uncertainty about the role of FcγR in U5 snRNP200 expression. The need to explore alternative mechanisms of U5 snRNP200 expression on tumor cells.

    Cell-surface expression of the RNA binding protein U5 snRNP200 on acute myeloid leukemia and other tumor cells is independent of FcγR-mediated interactions · 2026 · DOI

  • Limited methods are available for measuring kinetic constants in complex matrices. Existing methods have limitations, such as requiring external referencing.

    Focal Molography Allows for Affinity and Concentration Measurements of Proteins in Complex Matrices with High Accuracy · 2025 · DOI

  • The CA125 II test has limitations in its antibody coverage of the tandem repeat region. There is a need for characterizing the binding of new antibodies to improve diagnostic and screening tools. Prior studies have not fully characterized the binding of M11-like and OC125-like antibodies to CA125 tandem repeats.

    Characterization of M11-like and OC125-like Monoclonal Antibody Binding to CA125 Tandem Repeats · 2025 · DOI

  • There is a need for a method to quantify cell-antibody avidity. The existing methods do not provide a direct quantification of avidity.

    A New Approach to Examine Cell–Antibody Avidity with Surface Plasmon Resonance Imaging · 2025 · DOI

  • Data on changes in antibody and Fc receptor interactions after antibody binding to the target antigen are poorly covered in the literature. The paper identifies a need for a better understanding of the importance of this effect for pharmacokinetic properties and effector mechanisms.

    Changes in the Interaction Properties of Antibodies with Fc Receptors upon Binding to Target Antigens · 2025 · DOI

  • Immunoglobulin-based therapies are increasingly used to modulate neuroinflammatory diseases, yet it remains unclear whether they directly affect neuronal function.

    Immunoglobulins and Efgartigimod reduce neuronal activity in primary rat cortical neuron cultures · 2026 · DOI

  • It has been evaluated in Phase 1 and 2 studies in healthy volunteers and patients with chronic pruritic conditions and demonstrated anti‐pruritic efficacy in a Phase 2 study in prurigo nodularis, but detailed pharmacokinetic analysis has not been previously reported.

    Population Pharmacokinetic Analysis of Vixarelimab in Healthy Volunteers and Patients With Chronic Pruritic Conditions · 2026 · DOI

  • The lack of automation in computational protein engineering workflows. The need for a platform that can accelerate and democratize protein engineering.

    ProteinMCP: An Agentic AI Framework for Autonomous Protein Engineering · 2026 · DOI

  • The study did not explore alternative expression systems or modifications to the existing protocols. The yield of pure protein was less than 1mg per liter of culture, indicating the need for purification optimization.

    Investigation of the Effect of Arginine and Glutathione on Recovery of a Single Domain Antibody Produced in Bacteria in Inclusion Bodies · 2026 · DOI

  • The immune system's ability to recognize and neutralize pathogens is not fully understood. The process of affinity maturation trajectories for antibodies is complex.

    Taking the biology seriously makes models better · 2026 · DOI

  • Limited discriminative performance of Boltz-2 confidence metrics. Difficulty in distinguishing true binding from non-binding pairs at scale. Need for effective computational interaction prediction methods.

    Benchmarking Boltz-2 for Screening of Therapeutic Antibody-Antigen Interactions · 2026 · DOI

  • The study focuses on a specific problem of AB-AG discrimination. The dataset is limited to 519 monoclonal antibodies from Thera-SabDab. The paper does not explore other potential applications of Boltz-2.

    Benchmarking Boltz-2 for Screening of Therapeutic Antibody-Antigen Interactions · 2026 · DOI

  • Further studies are needed to assess the long-term effects of subcutaneous administration of antibody-drug conjugates with PH20. Additional research is required to evaluate the use of PH20 with other types of biologics. The development of subcutaneous formulations of antibody-drug conjugates with PH20 may be a promising area of research.

    Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigs · 2026 · DOI

  • The lack of effective subcutaneous delivery methods for antibody-drug conjugates. The need to improve injection performance and reduce local tissue toxicity associated with subcutaneous administration of the conjugates.

    Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigs · 2026 · DOI

  • The treatment of relapsed/refractory multiple myeloma is a major unmet clinical need. There is a need for further research on the efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies.

    Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies · 2026 · DOI

  • This study has several limitations. First, the included studies were mainly single-arm phase I/II clinical trials and retrospective real-world cohorts. No randomized controlled studies were available. Therefore, we could not directly compare efficacy or safety across different BsAbs, or between BsAbs and CAR-T-cell therapy.

    Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies · 2026 · DOI

  • The neutralizing activity of anti-drug antibodies (ADAs), especially neutralizing ADAs (nADAs) activity, should be examined considering that it can alter pharmacokinetic (PK) and pharmacodynamic (PD) profiles, reduce drug efficacy, and lead to life-threatening adverse events.

    Development and Validation of Cell-Based Bioassay for the Detection of Neutralizing Antibodies to Ocrelizumab in Human Serum Using Antibody-Dependent Cell-Mediated Cytotoxicity Test in a Reporter Cell Line Expressing FcγRIIIa · 2026 · DOI

  • There is a need to address antibody reproducibility issues in research. There is a need to characterize commercial antibodies for human proteins using standardized protocols.

    A guide to selecting high-performing antibodies for CTHRC1 (Q96CG8) for use in western blot and immunoprecipitation · 2026 · DOI

  • Inherent limitations are associated with the antibody characterization platform used in this study. Firstly, the YCharOS project focuses on renewable (recombinant and monoclonal) antibodies and does not test all commercially available CTHRC1 antibodies. YCharOS partners provide approximately 80% of all renewable antibodies, but some top-cited polyclonal antibodies may not be available through these partners.

    A guide to selecting high-performing antibodies for CTHRC1 (Q96CG8) for use in western blot and immunoprecipitation · 2026 · DOI

  • Further studies can be performed to characterize additional antibodies against KIF5A. The results can be used to guide the development of new antibodies against KIF5A.

    A guide to selecting high-performing renewable antibodies for KIF5A (Q12840) across western blot, immunoprecipitation, and immunofluorescence · 2026 · DOI

  • Further exploration of nanobody-based immunoassays in food safety testing, - Investigation of the potential applications of nanobody-based immunoassays in detecting food hazards, - Development of reliable diagnostic assays using…

    Nanobody-Based Immunoassays for the Detection of Food Hazards—A Review · 2025 · DOI

  • The use of alternate expression systems, such as Chinese Hamster Ovary cells, SimpleCells, or insect cells, could enable the expression of recalcitrant repeat proteins, - Further characterization of antibodies that bind more repeats and are suitable for spliceoform…

    Characterization of M11-like and OC125-like Monoclonal Antibody Binding to CA125 Tandem Repeats · 2025 · DOI

  • Further study of the effects of antibody binding to target antigens on Fc receptor interactions, - Investigation of the pharmacokinetic properties and effector mechanisms of action of therapeutic antibodies, - Development of new methods for screening and optimizing antibody interactions with Fc…

    Changes in the Interaction Properties of Antibodies with Fc Receptors upon Binding to Target Antigens · 2025 · DOI

  • Limited understanding of the potential effects of YTE substitutions on Fc-mediated functions - Limited understanding of the risk of immunogenicity - Limited understanding of differences in FcRn binding across…

    YTE-engineered antibodies: From neonatal Fc receptor binding mechanisms to next-generation therapeutics · 2026 · DOI

Most-cited papers in Monoclonal and Polyclonal Antibodies Research

Most recent work

Find a gap in your own Monoclonal and Polyclonal Antibodies Research sub-topic

This page shows what the Monoclonal and Polyclonal Antibodies Research literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) The lack of knowledge about how RNA binding proteins are anchored to the membrane of tumor cells (“Cell-surface expression of the RNA binding protein U5 snRNP200 on acute myeloid…”, 2026); (2) Immunoglobulin-based therapies are increasingly used to modulate neuroinflammatory diseases, yet it remains unclear whether they directly affect neuronal function (“Immunoglobulins and Efgartigimod reduce neuronal activity in primary rat…”, 2026); (3) The lack of automation in computational protein engineering workflows (“ProteinMCP: An Agentic AI Framework for Autonomous Protein Engineering”, 2026); (4) The immune system's ability to recognize and neutralize pathogens is not fully understood (“Taking the biology seriously makes models better”, 2026); (5) Further studies are needed to assess the long-term effects of subcutaneous administration of antibody-drug conjugates with PH20 (“Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant…”, 2026). 380 gap statements have been mined from Monoclonal and Polyclonal Antibodies Research papers in our 7.9M-paper local library, which holds 2,389 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.